期刊文献+

制备工艺对载牛血清白蛋白微粒的影响

Infl uence of Preparation Method on Properties of BSA-loaded Microparticles
原文传递
导出
摘要 将牛血清白蛋白(BSA)或BSA-锌复合物溶解或分散于聚L-丙交酯(PLLA)溶液中,再分别用乳化-溶剂蒸发法或凝胶模板法(聚乙烯醇模板)制备得到4种BSA-PLLA微粒,并表征其性能。结果表明,乳化-溶剂蒸发法所得的2种微粒(s/o/w和w/o/w微粒)和凝胶模板法所得的2种微粒(s/o/t和w/o/t微粒)平均粒径分别为38.13、34.65、49.47和45.82?m,跨距为0.77、0.86、0.22和0.26,包封率分别为15.62%、7.74%、85.87%和81.77%。前法制得的微粒包封率明显较低。体外释放试验中,上述4种微粒在d1的突释量分别为1.3%、13.3%、18.9%和55.7%,127 d的累积释放率为14.1%、83.6%、57.5%和60.6%。可见,制备方法会显著影响微粒的形态和结构,继而影响载药性能和释药特征。 Bovine serum albumin (BSA) or BSA-Zn complex was dissolved or dispersed in poly (L-lactic acid) (PLLA) solution, which were further loaded into microparticles by emulsion-solvent evaporation method or hydrogel template technique (with polyvinyl alcohol as a template). Then four kinds of microparticles were obtained and their properties were characterized. The average particle size of the former two (named as s/o/w and w/o/w microparticles) and the last two (named as s/o/t and w/o/t microparticles) were 38.13, 34.65, 49.47 and 45.82 μm, the span values were 0.77, 0.86, 0.22 and 0.26, the entrapment efficiencies were 15.62% , 7.74%, 85.87% and 81.77%, respectively. The drugloading capacities of the two kinds of micropartieles prepared by the former method were significantly decreased. The results of in vitro release test showed that the burst release at the first day of the above four products were 1.3 %, 13.3 %, 18.9% and 55.7%, the cumulative release at 127 d were 14.1%, 83.6%, 57.5% and 60.6%0, respectively. It indicated that morphology and structure of microparticles significantly affected by the preparation methods, which further impacted drug-loading efficiency and release profile.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2016年第1期44-48,共5页 Chinese Journal of Pharmaceuticals
基金 国家自然科学基金项目(81360644) 宁夏回族自治区科技支撑国际合作项目([2013]21号)
关键词 牛血清白蛋白 微粒 凝胶模板法 乳化-溶剂蒸发法 牛血清白蛋白-锌复合物 bovine serum albumin (BSA) microparticle hydrogel template emulsion-solvent evaporation method BSA-Zn complex
  • 相关文献

参考文献10

  • 1Jain RA. The manufacturing techniques of various drugloaded biodegradable poly (lactide-co-glycolide) (PLGA)devices [J]. Biomaterials, 2000, 21 (23): 2475—2490.
  • 2Jeyanthi R, Mehta RC, Thanoo BC, et al. Effect of processingparameters on the properties of peptide-containing PLGAmicrospheres [J]. JMicroencapsul, 1997,14(2): 163—174.
  • 3Ye M,Kim S,Park K. Issues in long-term protein deliveryusing biodegradable microparticles [J]. J Controlled Release,2010, 146(2): 241—260.
  • 4Yeo Y, Park K. Control of encapsulation efficiency and initialburst in polymeric microparticle systems [J]. Arch PharmRes, 2004, 27(1): 1—12.
  • 5Acharya G, Shin CS, McDermott M, et al. The hydrogeltemplate method for fabrication of homogeneous nano/microparticles [J]. J Controlled Release, 2010,141 (3):314—319.
  • 6Acharya G, Shin CS, Vedantham K, et al. A study of drugrelease from homogeneous PLGA microstructures [J]. JControlled Release, 2010, 146(2): 201—206.
  • 7孙美丽,班俊峰,黄思玉,吕竹芬.PLGA微球载药量和包封率的影响因素及控制[J].广东药学院学报,2011,27(6):643-648. 被引量:27
  • 8Lu Y, Sturek M, Park K. Microparticles produced by thehydrogel template method for sustained drug delivery [J].Int J Pharm, 2014, 461 (1-2): 258—269.
  • 9Wischke C, Schwendeman SP. Principles of encapsulatinghydrophobic drugs in PLA/PLGA microparticles [J]. Int JPharm, 2008, 364 (2): 298—327.
  • 10Luan X, Skupin M, Siepmann J, et al. Key parametersaffecting the initial release (burst) and encapsulationefficiency of peptide-containing poly (lactide-co-glycolide)microparticles [J]. Int J Pharm, 2006, 324 (2): 168—175.

二级参考文献9

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部